AbbVie (ABBV)
(Delayed Data from NYSE)
$196.82 USD
-0.14 (-0.07%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $196.77 -0.05 (-0.03%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$196.82 USD
-0.14 (-0.07%)
Updated Oct 2, 2024 04:00 PM ET
After-Market: $196.77 -0.05 (-0.03%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth D Momentum D VGM
Zacks News
AbbVie (ABBV) Stock Up Almost 17% in One Month: Here's Why
by Zacks Equity Research
AbbVie's (ABBV) shares have gained an impressive 16.7% in the past month supported by a series of positive news for the company in the past few weeks.
Biotech Stock Roundup: Endocyte Shoots up on Deal, Amgen-AbbVie Settle Humira Litigation
by Arpita Dutt
Key highlights this week include Amgen's (AMGN) agreement with AbbVie related to its biosimilar version of Humira and Endocyte's in-licensing deal which sent its shares soaring.
Will Gilead & AbbVie Benefit from Merck's Decision to Drop Two HCV Programs?
by Arpita Dutt
With Merck (MRK) discontinuing the development of two HCV candidates, here's a look at what to expect from the remaining key players in the HCV market.
Merck Drops Two HCV Combination Programs Amid Competition
by Zacks Equity Research
Merck (MRK) is discontinuing the development of two of its hepatitis C (HCV) programs - MK-3682B and MK-3682C - as the HCV market is becoming extremely crowded.
Gilead (GILD) Gets Approval for HCV Drug Sovaldi in China
by Zacks Equity Research
Gilead Sciences' (GILD) blockbuster hepatitis C virus (HCV) infection drug, Sovaldi is now approved in China also.
Biotech Stock Roundup: Amgen Reiterates 2017 Outlook, Intercept Hit by Ocaliva Safety Issues
by Arpita Dutt
Key highlights this week include Amgen's (AMGN) update regarding Hurricane Maria and safety issues concerning Intercept's Ocaliva.
Abbvie/Bristol-Myers Inks Deal to Develop Therapeutic Cancer
by Zacks Equity Research
AbbVie (ABBV) and Bristol-Myers Squibb entered into a deal to evaluate the combination of ABBV-399 and Opdivo (nivolumab) in c-Met overexpressing non-small cell lung cancer.
Gilead's (GILD) Epclusa Receives Label Expansion in Canada
by Zacks Equity Research
Gilead Sciences Inc. (GILD) announced that Health Canada has approved a label update of hepatitis C virus drug, Epclusa.
Biotech Stock Roundup: FDA Nod for First Cancer Biosimilar, HALO up on Deals, Raised Outlook
by Arpita Dutt
Data presentations, regulatory updates and licensing deals were among the key highlights this week with the focus being on the FDA approval of the first cancer biosimilar - Amgen's (AMGN) Mvasi.
Roche (RHHBY) Announces Positive Data on Leukemia Drug
by Zacks Equity Research
Roche Holdings AG (RHHBY) announced positive results from the phase III study, MURANO on leukemia drug Venclexta.
J&J's (JNJ) Psoriasis Drug Guselkumab Gets CHMP Nod in EU
by Zacks Equity Research
J&J's (JNJ) pipeline candidate, guselkumab for the treatment of moderate-to-severe plaque psoriasis received a positive opinion from the CHMP in the EU.
Novartis Announces Long-Term Data on Psoriasis Drug Cosentyx
by Zacks Equity Research
Novartis' (NVS) Cosentyx showed robust skin clearance data over a period of five years in patients with moderate-to-severe plaque psoriasis.
Biotech Stock Roundup: Alexion to Cut Jobs, Streamline Operations, Kura Up on Cancer Data
by Arpita Dutt
Key highlights include Alexion's (ALXN) restructuring plans and promising data from Kura Oncology on its lead pipeline candidate.
AbbVie's RA Candidate Meets Primary Endpoint in Phase III
by Zacks Equity Research
AbbVie's (ABBV) shares inch up with pipeline candidate upadacitinib meeting primary endpoints in a phase III study for treatment of rheumatoid arthritis.
AbbVie's Upadacitinib Meets Primary Endpoint in Phase IIb
by Zacks Equity Research
AbbVie's (ABBV) eczema candidate upadacitinib meets primary endpoints in a phase IIb trial for treating atopic dermatitis. The company aims to advance the candidate to the next study level in 2018.
Regeneron's Cemiplimab Gains Breakthrough Therapy Status
by Zacks Equity Research
Regeneron (REGN) and partner Sanofi's skin cancer candidate cemiplimab gets the FDA-granted Breakthrough Therapy status. The companies also anticipate submitting a BLA in the first-quarter 2018.
AbbVie Inc. (ABBV) in Focus: Stock Moves 6.1% Higher
by Zacks Equity Research
AbbVie (ABBV) was a big mover last session, as the company saw its shares rise more than 6% on the day amid huge volumes.
AbbVie Submits NDA for Endometriosis Candidate to the FDA
by Zacks Equity Research
AbbVie Inc. (ABBV) and partner Neurocrine Biosciences announced that the new drug application (NDA) for their pipeline candidate, elagolix, has been submitted to the FDA.
Forget Abbott, Buy These 4 High-Growth MedTech Stocks Instead
by Zacks Equity Research
The share price performance of Abbott Laboratories (ABT) has been disappointing over the last three years. Of the prime issues plaguing Abbott, foreign exchange is a major one.
The Zacks Analyst Blog Highlights: Gilead Sciences, Kite Pharma, AbbVie's and Novartis AG
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Gilead Sciences, Kite Pharma, AbbVie's and Novartis AG
Gilead to Fly High with Kite Pharma Acquisition for $11.9B
by Zacks Equity Research
Biotech giant Gilead Sciences, Inc. (GILD) announced that it will buy Kite Pharma, Inc. (KITE) to foray into the emerging field of cell therapy.
The Zacks Analyst Blog Highlights: AbbVie, Broadcom 21st Century Fox, Intuit and China Life Insurance
by Zacks Equity Research
The Zacks Analyst Blog Highlights: AbbVie, Broadcom 21st Century Fox, Intuit and China Life Insurance
Roche's Gazyva Gets Priority Review for Follicular Lymphoma
by Zacks Equity Research
Roche Holding AG (RHHBY) announced that the FDA has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review to leukaemia drug Gazyva.
Biogen's Humira Biosimilar Imraldi Gets Approval in EU
by Zacks Equity Research
Biogen Inc.'s (BIIB) biosimilar version of AbbVie's top-selling blockbuster drug, Humira has been approved by the European Commission.
Roche (RHHBY) Hemophilia A Drug Granted Priority Review
by Zacks Equity Research
Roche Holdings AG (RHHBY) announced that its Biologics License Application (BLA) for hemophilia A candidate, emicizumab has been accepted by the FDA and granted priority review.